Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$510.06 - $779.03
Previous CloseN/A
Volume151.62K
Average Volume (3M)392.23K
Market Cap
$44.89B
Enterprise Value$32.30B
Total Cash (Recent Filing)$3.93B
Total Debt (Recent Filing)$43.15M
Price to Earnings (P/E)34.6
Beta0.37
Next Earnings
Oct 30, 2025EPS Estimate
4.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.74
Shares Outstanding61,199,900
10 Day Avg. Volume397,128
30 Day Avg. Volume392,228
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)6.70
Price to Sales (P/S)16.81
P/FCF Ratio-243.71
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue14.08
Enterprise Value/Gross Profit21.27
Enterprise Value/Ebitda78.04
Forecast
1Y Price Target
$828.00Price Target Upside12.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Bulls Say, Bears Say
Bulls Say
Clinical TrialsResults from the trial indicated clinically meaningful improvements on the 6-minute walk test, which correlated with positive trends in arm and leg strength in patients on ARGX-119 compared to placebo.
Market LeadershipVyvgart continues to have a superior efficacy and safety profile across endpoints.
Product DevelopmentARGX-119 is advancing into Phase 3 development, with the company moving fast to capitalize on its first mover advantage in congenital myasthenic syndrome (CMS).
Bears Say
Competitive PressureVyvgart offers multiple dosing formulations providing flexibility to patients and physicians and the company is working on an autoinjector, which could further drive uptake into earlier lines of treatment.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $779.03 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $44.89B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Oct 30, 2025 which is in 37 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Jul 31, 2025. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $3.089 by $0.651.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 4.41.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,199,900 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $3.74 in its last earnings report, beating expectations of $3.089. Following the earnings report the stock price went up 11.929%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$828.00 (12.38% Upside)
$828.00 (12.38% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 166.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.36%
12-Months-Change
Fundamentals
Return on Equity
24.75%
Trailing 12-Months
Asset Growth
49.60%
Trailing 12-Months
Company Description
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX Company Deck
ARGX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth and expansion for VYVGART across global markets and indications, supported by financial performance and pipeline advancements. However, challenges include market dynamics in China, increased gross to net adjustments, and ongoing safety monitoring in CIDP.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$828.00
▲(12.38% Upside)
Technical Analysis
Ownership Overview
―
Insiders
15.80% Mutual Funds
19.37% Other Institutional Investors
63.83% Public Companies and
Individual Investors